Hims & Hers Health (HIMS) is down more than -11% after the FDA said Eli Lilly’s weight-loss drugs are no longer considered to be in shortage in the US, which threatens to undercut sales at Hims who ...

The mayor of Rio de Janeiro is promising to make a generic version of Ozempic available through the city’s public health ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Japan's Nikkei Stock 225 closed up by +1.97%. December 10-year T-notes (ZNZ24) Thursday closed down by -16.5 ticks.  The 10-year T-note yield rose +6.3 bp to 3.844%. Dec T-notes Thursday tumbled to a ...

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...